Display options
Cite
Pinheiro C, Granja S, Longatto-Filho A, et al. GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior. Oncotarget. 2017;8(38):63835-63845doi: 10.18632/oncotarget.19135.
Pinheiro, C., Granja, S., Longatto-Filho, A., Faria, A. M., Fragoso, M. C. B. V., Lovisolo, S. M., Bonatelli, M., Costa, R. F. A., Lerário, A. M., Almeida, M. Q., Baltazar, F., & Zerbini, M. C. N. (2017). GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior. Oncotarget, 8(38), 63835-63845. https://doi.org/10.18632/oncotarget.19135
Pinheiro, Céline, et al. "GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior." Oncotarget vol. 8,38 (2017): 63835-63845. doi: https://doi.org/10.18632/oncotarget.19135
Pinheiro C, Granja S, Longatto-Filho A, Faria AM, Fragoso MCBV, Lovisolo SM, Bonatelli M, Costa RFA, Lerário AM, Almeida MQ, Baltazar F, Zerbini MCN. GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior. Oncotarget. 2017 Jul 10;8(38):63835-63845. doi: 10.18632/oncotarget.19135. eCollection 2017 Sep 08. PMID: 28969033; PMCID: PMC5609965.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 10;8(38):63835-63845. doi: 10.18632/oncotarget.19135. eCollection 2017 Sep 08.

GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior.

Oncotarget

Céline Pinheiro, Sara Granja, Adhemar Longatto-Filho, André M Faria, Maria C B V Fragoso, Silvana M Lovisolo, Murilo Bonatelli, Ricardo F A Costa, Antonio M Lerário, Madson Q Almeida, Fátima Baltazar, Maria C N Zerbini

Affiliations

  1. Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
  2. ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
  3. Barretos School of Health Sciences Dr. Paulo Prata - FACISB, São Paulo, Brazil.
  4. Molecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, Brazil.
  5. Laboratory of Medical Investigation (LIM-14), School of Medicina, University of São Paulo, São Paulo, Brazil.
  6. Unidade de Suprarrenal, Disciplina de Endocrinologia e Metabologia, Laboratório de Hormônios e Genética Molecular LIM42, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  7. Instituto do Câncer do Estado de São Paulo - ICESP, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  8. Hospital Universitário, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  9. Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA.
  10. Departamento de Patologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

PMID: 28969033 PMCID: PMC5609965 DOI: 10.18632/oncotarget.19135

Abstract

BACKGROUND: Discrimination between benign and malignant tumors is a challenging process in pediatric adrenocortical tumors. New insights in the metabolic profile of pediatric adrenocortical tumors may contribute to this distinction, predict prognosis, as well as identify new molecular targets for therapy. The aim of this work is to characterize the expression of the metabolism-related proteins MCT1, MCT2, MCT4, CD147, CD44, GLUT1 and CAIX in a series of pediatric adrenocortical tumors.

METHODS: A total of 50 pediatric patients presenting adrenocortical tumors, including 41 clinically benign and 9 clinically malignant tumors, were included. Protein expression was evaluated using immunohistochemistry in samples arranged in tissue microarrays.

RESULTS: The immunohistochemical analysis showed a significant increase in plasma membrane expression of GLUT1 in malignant lesions, when compared to benign lesions (

CONCLUSION: GLUT1 expression was differentially expressed in pediatric adrenocortical tumors, with higher expression in clinically malignant tumors, and associated with shorter survival, suggesting a metabolic remodeling towards a hyperglycolytic phenotype in this malignancy.

Keywords: Warburg effect; glucose transporter; metabolic reprogramming; monocarboxylate transporter; pediatric adrenocortical tumors

Conflict of interest statement

CONFLICTS OF INTEREST The authors have nothing to disclose.

References

  1. J Clin Endocrinol Metab. 2001 Oct;86(10):4970-3 - PubMed
  2. J Pediatr Surg. 2016 Jan;51(1):172-7 - PubMed
  3. J Pediatr Surg. 2011 Jun;46(6):1201-7 - PubMed
  4. Trends Cancer. 2016 Jul;2(7):365-377 - PubMed
  5. Pediatr Surg Int. 2015 Jun;31(6):563-71 - PubMed
  6. Hell J Nucl Med. 2015 May-Aug;18(2):97-102 - PubMed
  7. Nat Rev Cancer. 2004 Nov;4(11):891-9 - PubMed
  8. World J Surg. 2010 Jul;34(7):1506-10 - PubMed
  9. Mol Cell Endocrinol. 2012 Mar 31;351(1):52-7 - PubMed
  10. Curr Drug Metab. 2015;16(3):221-42 - PubMed
  11. Nat Rev Cancer. 2011 Feb;11(2):85-95 - PubMed
  12. Sci Transl Med. 2011 Aug 3;3(94):94ra70 - PubMed
  13. Int J Obes (Lond). 2008 Sep;32 Suppl 4:S36-41 - PubMed
  14. Am J Surg Pathol. 2003 Jul;27(7):867-81 - PubMed
  15. Cell Physiol Biochem. 2013;32(6):1845-56 - PubMed
  16. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2066-73 - PubMed
  17. Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5 - PubMed
  18. Virchows Arch. 2008 Feb;452(2):139-46 - PubMed
  19. J Biomed Biotechnol. 2010;2010:427694 - PubMed
  20. Ann Intern Med. 2003 Mar 4;138(5):424-9 - PubMed
  21. Front Endocrinol (Lausanne). 2015 Feb 18;6:23 - PubMed
  22. Cancer J. 2015 Mar-Apr;21(2):88-96 - PubMed
  23. Nat Rev Endocrinol. 2011 Jun;7(6):323-35 - PubMed
  24. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  25. Endocr Relat Cancer. 2015 Jun;23 (6):481-93 - PubMed
  26. Nat Rev Drug Discov. 2011 Aug 31;10(9):671-84 - PubMed
  27. Pediatr Radiol. 2000 May;30(5):306 - PubMed
  28. Curr Opin Endocrinol Diabetes Obes. 2013 Jun;20(3):192-7 - PubMed
  29. Asian Pac J Cancer Prev. 2014;15(17):7037-41 - PubMed
  30. Endocr Rev. 2014 Apr;35(2):282-326 - PubMed
  31. Horm Cancer. 2011 Dec;2(6):354-62 - PubMed
  32. J Bioenerg Biomembr. 2012 Feb;44(1):141-53 - PubMed
  33. Diagn Pathol. 2014 Nov 14;9:211 - PubMed
  34. Endocr Relat Cancer. 2009 Sep;16(3):919-28 - PubMed
  35. Rev Hosp Clin Fac Med Sao Paulo. 2002 Nov-Dec;57(6):251-6 - PubMed
  36. Cancer. 2009 Jan 15;115(2):243-50 - PubMed
  37. Horm Cancer. 2011 Dec;2(6):333-40 - PubMed
  38. J Clin Oncol. 2004 Mar 1;22(5):838-45 - PubMed
  39. J Clin Endocrinol Metab. 2008 Sep;93(9):3524-31 - PubMed
  40. Endocr Relat Cancer. 2013 Aug 28;20(5):705-16 - PubMed
  41. Mol Cell Endocrinol. 2012 Mar 31;351(1):44-51 - PubMed
  42. J Pediatr Surg. 2008 May;43(5):843-9 - PubMed
  43. J Clin Endocrinol Metab. 1997 Jul;82(7):2027-31 - PubMed
  44. J Clin Endocrinol Metab. 2000 May;85(5):2048-56 - PubMed
  45. J Urol. 1995 Dec;154(6):2004-9 - PubMed
  46. Expert Opin Ther Targets. 2009 Dec;13(12 ):1411-27 - PubMed
  47. Mol Cancer Ther. 2008 Sep;7(9):2599-608 - PubMed
  48. Oncotarget. 2015 Dec 29;6(42):44403-21 - PubMed
  49. J Pediatr Surg. 2004 May;39(5):759-63 - PubMed
  50. Arq Bras Endocrinol Metabol. 2004 Oct;48(5):647-50 - PubMed
  51. J Cell Mol Med. 2010 Apr;14(4):771-94 - PubMed
  52. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S714-20 - PubMed
  53. Cancer Res. 2007 Jan 15;67(2):600-8 - PubMed
  54. PLoS One. 2014 Feb 03;9(2):e87951 - PubMed
  55. J Pediatr Surg. 2013 May;48(5):1025-31 - PubMed
  56. Histol Histopathol. 2011 Oct;26(10 ):1279-86 - PubMed
  57. J Pediatr Surg. 2008 Dec;43(12 ):2186-92 - PubMed
  58. Histol Histopathol. 2014 Dec;29(12 ):1511-24 - PubMed
  59. J Clin Endocrinol Metab. 2013 Dec;98(12):4551-64 - PubMed
  60. Nat Rev Cancer. 2010 Apr;10(4):267-77 - PubMed
  61. Am J Surg Pathol. 1984 Mar;8(3):163-9 - PubMed

Publication Types